One-Year Comparative Effectiveness of Upadacitinib vs Tofacitinib for Ulcerative Colitis: A Multicenter Cohort Study

被引：8
|
作者：
Dalal, Rahul S. [1 ]
Kallumkal, Govind [2 ]
Cabral, Heidy J. [1 ]
Barnes, Edward L. [3 ]
Allegretti, Jessica R. [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Gastroenterol Hepatol & Endoscopy, Boston, MA 02115 USA
[2] Univ N Carolina, Dept Med, Chapel Hill, NC USA
[3] Univ N Carolina, Dept Med, Div Gastroenterol, Chapel Hill, NC USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 08期
关键词：
small molecule; Janus kinase inhibitor; inflammatory bowel disease; remission; biologic; MAINTENANCE THERAPY; INDUCTION;
D O I：
10.14309/ajg.0000000000002746
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
INTRODUCTION: The comparative effectiveness of upadacitinib and tofacitinib for ulcerative colitis (UC) is poorly understood. METHODS: In this retrospective cohort study, we compared steroid-free clinical remission (SFCR) and endoscopic response/remission at 52 weeks among adults initiating upadacitinib or tofacitinib for UC. RESULTS: A total of 155 patients initiated upadacitinib (n = 81; 30% prior tofacitinib exposure) or tofacitinib (n = 74; 0% prior upadacitinib exposure). After inverse probability of treatment-weighted logistic regression, upadacitinib was associated with significantly higher odds of SFCR (odds ratio 3.01, 95% confidence interval 1.39-6.55) vs tofacitinib. There were no differences for endoscopic response/remission. DISCUSSION: Upadacitinib was more effective at achieving SFCR in UC at 52 weeks vs tofacitinib.
引用
收藏
页码：1628 / 1631
页数：4
相关论文
共 50 条
  • [1] ONE-YEAR COMPARATIVE EFFECTIVENESS OF UPADACITINIB VERSUS TOFACITINIB FOR ULCERATIVE COLITIS: A MULTICENTER COHORT STUDY
    Dalal, Rahul S.
    Kallumkal, Govind
    Cabral, Heidy
    Barnes, Edward L.
    Allegretti, Jessica R.
    GASTROENTEROLOGY, 2024, 166 (05) : S56 - S57
  • [2] Comparative Effectiveness of Upadacitinib vs Ustekinumab for Ulcerative Colitis: A Multicenter Retrospective Cohort Study
    Dalal, Rahul S.
    Kallumkal, Govind
    Cabral, Heidy J.
    Bachour, Salam
    Barnes, Edward L.
    Allegretti, Jessica R.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (03) : 666 - 668
  • [3] Comparative Effectiveness of Upadacitinib and Tofacitinib in Ulcerative Colitis: A US Propensity-Matched Cohort Study
    Kochhar, Gursimran S.
    Khataniar, Himsikhar
    Jairath, Vipul
    Farraye, Francis A.
    Desai, Aakash
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (12): : 2471 - 2479
  • [4] Comparative Effectiveness of Upadacitinib vs Ustekinumab for Ulcerative Colitis at 8-16 Weeks: A Multicenter Retrospective Cohort Study
    Dalal, Rahul
    Kallumkal, Govind
    Cabral, Heidy
    Bachour, Salam
    Barnes, Edward
    Allegretti, Jessica R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S628 - S630
  • [5] Comparative short-term effectiveness of tofacitinib and upadacitinib in refractory, moderate-to-severe ulcerative colitis - An international, multicenter cohort study
    Farkas, B.
    Resal, T.
    Lakatos, P. L.
    Limdi, J. K.
    Armuzzi, A.
    Bezzio, C.
    Savarino, E., V
    Saibeni, S.
    Michalopoulos, G.
    Attauabi, M.
    Seidelin, J. B.
    Fousekis, F. S.
    Katsanos, K.
    Bacsur, P.
    Ivany, E.
    Balint, A.
    Szepes, Z.
    Farkas, K.
    Molnar, T.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1860 - i1861
  • [6] One-Year Comparative Effectiveness of Ustekinumab vs Tofacitinib for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure
    Dalal, Rahul
    Sharma, Puza
    Bains, Kanwal
    Pruce, Jordan
    Allegretti, Jessica R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S501 - S502
  • [7] Comparative Effectiveness of Upadacitinib and Tofacitinib in Inducing Remission in Ulcerative Colitis: Real-World Data
    Boneschansker, Leo
    Ananthakrishnan, Ashwin N.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (09) : 2427 - +
  • [8] Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study
    Gabrielli, Anna Maria Carvalhas
    Ferretti, Francesca
    Monico, Camilla Maria
    Tombetti, Enrico
    Maconi, Giovanni
    Romeo, Samanta
    Sed, Nicole Piazza O.
    Caprioli, Flavio
    Mazzola, Anna Maria
    Alicante, Saverio
    Berte, Roberto
    Lolli, Elisabetta
    Scribano, Maria Lia
    Buscarini, Elisabetta
    Ricci, Chiara
    Carmagnola, Stefania
    Ardizzone, Sandro
    Cannatelli, Rosanna
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (05) : 1785 - 1792
  • [9] Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety
    Parra, Rogerio Serafim
    Froes, Renata de Sa Brito
    Magro, Daniela Oliveira
    da Costa Ferreira, Sandro
    de Mello, Munique Kurtz
    de Azevedo, Matheus Freitas Cardoso
    Damiao, Aderson Omar Mourao Cintra
    de Sousa Carlos, Alexandre
    Barros, Luisa Leite
    de Miranda, Maria Luiza Queiroz
    Vieira, Andrea
    Sales, Marcos Paulo Moraes
    Zabot, Gilmara Pandolfo
    Cassol, Ornella Sari
    Alves Jr, Antonio Jose Tiburcio
    Lubini, Marcio
    Machado, Marta Brenner
    Flores, Cristina
    Teixeira, Fabio Vieira
    Coy, Claudio Saddy Rodrigues
    Zaltman, Cyrla
    Chebli, Liliana Andrade
    Sassaki, Ligia Yukie
    Feres, Omar
    Chebli, Julio Maria Fonseca
    BMC GASTROENTEROLOGY, 2025, 25 (01)
  • [10] One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy
    Chiappetta, Michele Francesco
    Viola, Anna
    Mastronardi, Mauro
    Turchini, Laura
    Carparelli, Sonia
    Orlando, Adele
    Biscaglia, Giuseppe
    Miranda, Agnese
    Guida, Laura
    Costantino, Giuseppe
    Scaldaferri, Franco
    Bossa, Fabrizio
    Renna, Sara
    Cappello, Maria
    Alibrandi, Angela
    Orlando, Ambrogio
    Armuzzi, Alessandro
    Fries, Walter
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (11) : 1483 - 1489
12345